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a b s t r a c t
Lynch syndrome was formerly known as Hereditary Nonpolyposis Colorectal Cancer. Cur-
rently, these two nomenclatures each have their unique definitions and are no longer 
used interchangeably. The history of hereditary nonpolyposis colorectal cancer was first 
recognized formally in the literature by Henry Lynch in 1967. With advances of molecular 
genetics, there has been a transformation from clinical phenotype to genotype diagnos-
tics. This has led to the ability to diagnose affected patients before they manifest with 
cancer, and therefore allow preventative surveillance strategies. Genotype diagnostics 
has shown a difference in penetrance of different cancer risks dependent on the gene 
containing the mutation. Surgery is recommended as prevention for some cancers; for 
others they are reserved for once cancer is noted. Various surveillance strategies are rec-
ommended dependent on the relative risk of cancer and the ability to intervene with 
surgery to impact on survival. Risk reduction through aspirin has shown some recent 
promise, and continues to be studied.
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Revisão histórica da síndrome de Lynch
A síndrome de Lynch era anteriormente conhecida como “câncer colorretal hereditário não 
polipose”. Atualmente, essas duas nomenclaturas têm, cada uma, sua própria definição 
original e já não são empregadas de forma intercambiável. O histórico de câncer colorretal 
hereditário não polipose foi formalmente reconhecido pela primeira vez na literatura por 
Henry Lynch em 1967. Com os avanços da genética molecular, verificou-se uma mudança 
do fenótipo clínico para o diagnóstico genotípico. Esse fato levou à capacidade de diagnos-
ticar pacientes afetados antes que o câncer se manifestasse, e, portanto, à utilização de 
estratégias preventivas de rastreamento. O diagnóstico genotípico mostrou a diferença na 
penetrância de diferentes riscos de câncer dependendo do gene que contem a mutação. 
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
Este é um artigo Open Access sob a licença de CC BY-NC-ND
J  C O L O P R O C T O L .  2 0 1 3 ; 3 3 ( 2 ) : 9 5 – 1 1 096
Imunohistoquímica: IHQ
Câncer familial
Síndrome de Muir-Torre
Síndrome de Turcot
Família X
Reparação de incompatibilidade
A cirurgia é recomendada para a prevenção de alguns tipos de câncer; para outros, ela é 
reservada quando há o aparecimento da doença. Várias estratégias de rastreamento são re-
comendadas, dependendo do risco relativo de câncer, bem como a capacidade para intervir 
com a cirurgia objetivando um impacto na sobrevivência. A redução do risco através do uso 
de aspirina recentemente mostrou ser promissor e continua a ser estudada. 
Introduction
Lynch syndrome is a hereditary disorder with an autoso-
mal dominant transmission. In addition to colorectal can-
cer (CRC), those affected are at increased risk of secondary 
cancers such as: ovarian, uterine, renal urinary collecting 
system (transitional cell of renal pelvis and ureter), gastric, 
sebaceous gland adenomas /adenocarcinomas and brain. 
Since 1967, when Dr. Lynch first described the association of 
inheritance and adenocarcinoma of the colon in 1967,1  there 
have been many advances, and many of these just in the 
past 10 years.
History
Dr. Warthin, a University of Michigan pathologist, first de-
scribed a family affected with multiple cancers. His seam-
stress would lament her inevitable death due to cancer, as 
had occurred with many of her family members. She did suc-
cumb to endometrial cancer. Dr. Warthin drew her family tree 
and labeled it as Family G, as the family immigrated to Amer-
ica from Germany.2 See Fig. 1.3
This information laid somewhat dormant until Dr. Henry 
Lynch had met with a later generation of University of Michi-
gan pathologists who reintroduced this family tree to him. 
He found it similar to other families he had been following 
in Nebraska (Family N) since he was a second year medicine 
resident.4
Dr. Lynch met a lot of skepticism as he presented a heredi-
tary link, as at that time the focus was on the environment 
and its relationship with cancer. The strong consensus at that 
time was that the familial occurrences were due to similar 
carcinogen exposures. 
Patterns emerged as Lynch continued to follow the family. 
He noted in this Nebraska family that the offspring of affect-
ed parents had a cumulative risk of 54.1%, compared to 3.6% 
amongst offspring of unaffected parents. He also noted a pre-
dilection for the proximal colon in his families vs. the general 
population. Out of the 14 that were successfully treated for 
their colon cancer by local resection, 11 developed a second 
colon cancer 2-23 years later, with a mean of 8 years. There-
fore, Dr. Lynch dutifully noted the autosomal transmission, 
the proximal location and propensity for multiple cancers 
over 30 years ago.5
The terminology describing this syndrome has undergone 
transformations throughout the years. Therefore, caution is 
recommended as you read earlier manuscripts, as the co-
horts of patients were not always a homogenous group. The 
terminology Hereditary Nonpolyposis Colorectal Cancer and 
Lynch syndrome was first used in 1985.6,7,8 These two terms 
were used interchangeably until Dr. Jass’ 2006 article better 
defined Lynch syndrome as a disease with a proven mismatch 
repair gene mutation with vertical transmission regardless of 
age. Prior to 2006 the terminologies were used interchange-
ably, and at times studies compared apples to oranges. As we 
know now and will discuss later there are other families with 
patterns similar to Lynch syndrome but that are not proven to 
have a mismatch repair gene as their cause for their cancer 
predilection. In this review we will reserve Lynch syndrome 
to describe those with a proven mismatch repair gene muta-
tion.9
Transforming from phenotype diagnosis to 
genotype diagnosis
In the 1970’s and 1980’s, the gene mutations giving rise to 
Lynch syndrome were unknown. The diagnosis was made 
only by family history.  It was not until 1990 that a collabora-
tive effort was made to make consensus criteria for diagnosis. 
In 1990 the Amsterdam criteria were decided on by a group of 
scientists with special interests on hereditary disorders at the 
International Collaborative Group meeting in Amsterdam. It 
was published in 1991 (Table 1). The goal was to use this defi-
nition to then place these families with common patterns in 
collaborative studies.10
To allow for the incorporation of many of the secondary 
cancers noted in these families (cancers of the endometrium, Fig. 1 – Amsterdam I criteria. 
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small bowel or pelvic-ureter system), the criteria were later 
revised as Amsterdam II.11 See Table 2.
With each variation that followed, the goal was to increase 
awareness. Therefore newer criteria accepted a higher sensi-
tivity for lower specificity. Newer criteria also began to incor-
porate common histopathological findings that were noted in 
these colon cancers. The role of pathologists to help identify 
these patients emerged. As early as 1986, Mecklin and Järvin-
en noted certain features in the histology of the colon cancers 
in these families. This included features such as poor differ-
entiation, and abundant mucin secretion marked lymphocyt-
ic infiltrations. The adenomas were also noted to  transform 
to cancer within a shorter time frame.12
It was not until 1996 that a formal evaluation of these his-
topathological findings was reviewed. In Bethesda, The Early 
Detection Branch of the National Cancer Institute convened in 
a workshop entitled “The intersection of Pathology and Genet-
ics in the Hereditary Nonpolyposis Colorectal Cancer (HNPCC) 
Syndrome”. From this ensued a list of guidelines to identify 
those who should be tested for microsatellite instability.  This 
became known as the Bethesda Guidelines.13 See Table 3. 
NCI held another workshop in 2002 that led to the Revised 
Bethesda Criteria14 (Table 4). In this interim the standard pan-
els for microsatellite instability testing were agreed upon. 
Also at this time three mismatch repair genes were found 
to be the cause of Lynch: MLH1 MSH2, and MSH6. The main 
difference in these two guidelines was that the evaluation of 
polyps in young patients was discarded, the age range was ex-
panded to incorporate more testing, and second degree rela-
tives histories were included as a risk assessment.  
The University of Pittsburgh showed that the incorpora-
tion of the pathologist aided in the increase of identification 
of high-risk patients in comparison to relying only on clinical 
family history information. This allowed more pathologists to 
then undergo further testing such as IHC and/or genetic test-
ing.  While 8 out of 75 CRC patients were identified with earlier 
criteria, this increased to 17/75 using the revised guidelines. 
In the additional 9 that were identified 3 had absent MSH2 on 
IHC, 6 had absent MLH1.  This was an earlier study and IHC on 
MSH6 and PMS2 were not yet incorporated in their IHC algo-
rithm. Therefore this is a minimum identification.15
Table 1 – Amsterdam I criteria.
Amsterdam I
3 FDR with CRC, one of whom is  FDR relative to the other two; and
2 generations affected; and
1 of the affected <50 years of age; and
Familial Adenomatous Polyposis has been ruled out
Table 2 – Amsterdam II criteria.
Amsterdam II
3 or more relatives with a Lynch associated cancer (colorectal, 
endometrial, small intestine, ureter, renal pelvis); and
2 or more successive generations affected, one is a first-degree 
relative of the other two; and
1 or more relatives is diagnosed before the age of 50; and
Familial Adenomatous Polyposis has been ruled out
Tumors should be verified by pathologic examination.
Table 3 – Bethesda guidelines.
Individuals with cancer in families that meet the 
Amsterdam criteria
r*OEJWJEVBMTXJUIUXP)/1$$SFMBUFEDBODFSTJODMVEJOH
synchronous and metachronous colorectal cancers or associated 
extracolonic cancersa
r*OEJWJEVBMTXJUIDPMPSFDUBMDBODFSBOEBàSTUEFHSFFSFMBUJWFXJUI
colorectal cancer and/or HNPCC-related extracolonic cancer and/
or a colorectal adenoma; one of the cancers diagnosed at age < 45 y, 
and the adenoma diagnosed at age < 40 y
r*OEJWJEVBMTXJUIDPMPSFDUBMDBODFSPSFOEPNFUSJBMDBODFS
diagnosed at age < 45 y
r*OEJWJEVBMTXJUISJHIUTJEFEDPMPSFDUBMDBODFSXJUIBO
undifferentiated pattern (solid/cribriform) on histopathology 
diagnosed at age < 45 yb
r*OEJWJEVBMTXJUITJHOFUSJOHDFMMUZQFDPMPSFDUBMDBODFSEJBHOPTFE
at age < 45 yc
r*OEJWJEVBMTXJUIBEFOPNBTEJBHOPTFEBUBHFZ
a Endometrial, ovarian, gastric, hepatobiliary, or small-bowel 
cancer or transitional cell carcinoma of the renal pelvis or ureter.
b Solid/cribriform defined as poorly differentiated or 
undifferentiated carcinoma composed of irregular, solid sheets of 
large eosinophilic cells and containing small gland-like spaces.
c Composed of > 50% signet ring cells.
This concept of testing tumors in an automatic sequence 
by pathologists had mixed implementation. Many clinicians 
and pathologists had concerns that PCR and IHC testing on 
the specimens were considered genetic testing and should 
not be performed without consent. Therefore, some institu-
tions did incorporate this testing on their consent forms for 
colon resections. Other institutions felt that this was testing 
on the tumor and therefore no more indicative of labeling 
someone as Lynch short of taking a family history. It was the 
combination of Heather Hampel’s landmark study in 200516 
which was revisited in 2008,17 and the EGAPP group,18 Dr. Jass’ 
definition of Lynch,9 and the passage of the Genetic Informa-
tion Nondiscrimination Act (GINA)19 that led to the ground-
work  for the ability to do universal screening. These will be 
discussed in more details later in the paper. 
History of microsatellite instability (MSI) and 
immunohistochemistry (IHC) testing
Microsatellites are stretches of DNA with a repetitive se-
quence of nucleotides (e.g., CCCCC or CGACCACGA). These 
areas are susceptible to errors when a mismatch repair gene 
(i.e. MLH1, MSH2, MSH6, PMS2) function is impaired. The mis-
match repair genes function is to repair these errors. Without 
repair there is an accelerated accumulation of single nucle-
otide mutations and alterations in the length of simple re-
petitive microsatellites. Cancers arising in cells with defective 
mismatch repair (MMR) gene function exhibit an inconsistent 
number of microsatellite nucleotide repeats when compared 
to normal tissue, a finding referred to as “microsatellite in-
stability”. This can be tested by polymerase chain reaction 
(PCR). In 1992, three groups independently published results 
that recognized the link between microsatellite instability 
and Lynch syndrome.20,21,22 Thibodeau20 noted that there was 
a preponderance of cancer in the proximal location and also 
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noted enhanced survival in patients with Lynch syndrome 
when compared to sporadic cases. Peltomaki21 referred to it 
as replication error (RER) phenotype. Alltonen22 linked the lo-
cus that would later help to identify the actual MMR genes 
responsible. 
To facilitate communication among investigators, The Ear-
ly Detection Branch sponsored a third workshop entitled the 
“International Workshop on Microsatellite Instability and RER 
Phenotypes in Cancer Detection and Familial Predisposition” 
on December 8-9th, 1997. Over 120 investigators attended. The 
goal was to define uniform criteria for MSI; to propose tech-
nical guidelines for its detection; to review the literature per-
taining to the implications of this phenotype; and to develop 
a research agenda for future research. In particular, their high 
priority was to identify potential areas of clinical application to 
cancer detection, prognosis, and therapeutic response. At this 
meeting, MSI was defi ned as a change of any length due to ei-
ther insertion or deletion of repeating units in a microsatellite 
within a tumor when compared to normal tissue. It was at this 
meeting that the Bethesda Panel was proposed. These were to 
be the specific markers for MSI assessment, including BAT25, 
BAT26, D5S346, D2S123 and  D17S250. If two or more of the 
five microsatellites tested in the tumor were mutated it was 
termed MSI-high (MSI-H).  If one was mutated it was termed 
MSI-Low (MSI-L) and if none, MS-Stable (MSS).23 See Table 5.
Boland’s article23 that summarized the proceedings 
stressed that MSI-H in itself was not to be diagnostic of Lynch 
syndrome. While MSI-H was noted in 95% of those with 
HNPCC cancers that met Amsterdam criteria, and in 47% of 
cancers in families considered high risk but not meeting Am-
sterdam criteria, it was also noted in 13% of those with spo-
radic cancers. In fact, in Hampel’s 2005 paper (24), only 28.1% 
of their patients who were MSI-H were found to carry a Lynch-
associated mutation. 
In 1993, the same year that the link between MSI and Lynch 
syndrome was reported, mutations discovered in the mis-
match repair gene, MSH2, were found to be associated with 
the syndrome.24,25 Mutations in MLH1 and PMS2 were reported 
in 199426-29 and MSH6 in 1997.30,31 The discovery of these genes 
led the way for IHC testing and then to guide gene testing. 
IHC allows one to use antibodies to stain for the proteins 
produced by the MMR genes. A lack of staining is suggestive, 
but not indicative, of a mutation in the corresponding gene. 
MMR protein can be present but non-functional, and therefore 
can present with false positive results.32 In fact, there were 
reports of MSH2 being absent on IHC testing, but no MSH2 
mutation could be found. It is now known that this is due 
to an epimutation that leads to a silencing of MSH2. Chan33 
noted this linked deletion of 3’ terminal end of epithelial cell 
adhesion molecule, EPCAM gene (formerly TACSTD1) to Lynch 
syndrome. EPCAM is located upstream from MSH2. Gross 
deletions that disrupt the 3’ end of EPCAM deletion leads to 
methylation induction of the promoter regions of MSH2. This 
has been reported in up to 19-30% of individuals with MSI 
and absence of MSH2 on IHC.34,35,36 As commercial testing for 
each gene became available, the corresponding proteins were 
added to IHC panels.
MSI testing can be complementary to IHC testing, as false 
negatives can occur when the MMR protein is present but 
non-functional. MSI testing can be done with very little tissue 
and is highly reproducible.32 
But because it requires microdissection and molecular 
analysis it is not readily available at all centers. Additionally, 
Table 4 – Revised Bethesda guidelines.
Tumors from individuals should be tested for MSI in the 
following situations:
r$PMPSFDUBMDBODFSEJBHOPTFEJOBQBUJFOUXIPJTMFTTUIBO
years of age
r1SFTFODFPGTZODISPOPVTNFUBDISPOPVTDPMPSFDUBMPSPUIFS
HNPCC- associated tumorsa regardless of age
r$PMPSFDUBMDBODFSXJUIUIF.4*)b histologyc diagnosed in a 
patient who is less than 60 years of aged
r$PMPSFDUBMDBODFSEJBHOPTFEJOPOFPSNPSFàSTUEFHSFFSFMBUJWFT
with an HNPCC-related tumor, with one of the cancers being 
diagnosed under 50 years of age
r$PMPSFDUBMDBODFSEJBHOPTFEJOUXPPSNPSFàSTUPSTFDPOE
degree relatives with HNPCC-related tumors, regardless of age
r)FSFEJUBSZOPOQPMZQPTJTDPMPSFDUBMDBODFS	)/1$$
SFMBUFE
tumors including colorectal, endometrial, stomach, ovarian, 
pancreas, ureter and renal pelvis, biliary tract, and brain (usually 
glioblastoma as seen in Turcot syndrome) tumors, sebaceous 
gland adenomas and keratoacanthomas in Muir–Torre syndrome, 
and carcinoma of the small bowel
a Hereditary Nonpolyposis Colorectal Cancer (HNPCC)-related 
tumors include colorectal, endometrial, stomach, ovarian, 
pancreas, bladder, ureter and renal pelvis, biliary tract, brain 
(usually glioblastoma as seen in Turcot Syndrome), sebaceous 
gland adenomas and keratoacanthomas in Muir-Torre syndrome, 
and carcinoma of the small bowel.
b MSI-H, microsatellite instability–high in tumors refers to changes 
in two or more of the five National Cancer Institute-recommended 
panels of microsatellite markers.
c Presence of tumor infiltrating lymphocytes, Crohn’s-like 
lymphocytic reaction, mucinous/signet-ring differentiation, or 
medullary growth pattern.
d There was no consensus among the Workshop participants 
on whether to include the age criteria in guideline 3 above; 
participants voted to keep less than 60 years of age in the 
guidelines.
Table 5 – Recommendations for the evaluation of MSI-H 
and MSI-L.
The original National Cancer Institute (NCI) microsatellite 
panel included BAT25, BAT26, D2S123, D5S346 and 
D17S2507; however, the following caveats may apply:
r*GPOMZEJOVDMFPUJEFSFQFBUTBSFNVUBUFEUFTUBTFDPOEBSZQBOFM
of microsatellite markers with mononucleotide repeats (e.g., 
BAT40 and/or  MYCL) to exclude MSI-L.
r%JOVDMFPUJEFSFQFBUTBSFMFTTTFOTJUJWFUIBONPOPOVDMFPUJEF
repeats for MSI-H; however, they provide an internal control for 
the prevention of sample mix-up
r"QFOUBQMFYQBOFMPGàWFRVBTJNPOPNPSQIJDNPOPOVDMFPUJEF
repeats may be more sensitive for MSI-H tumors than other 
microsatellite markers and may obviate the need for normal 
tissue for comparison; this approach requires three or more 
mutant alleles to indicate MSI-H 
a MSI-H, microsatellite instability–high in tumors refers to changes 
in two or more of the five National Cancer Institute-recommended 
panels of microsatellite markers in tumors. MSI-L, microsatellite 
instability–low in tumors refers to changes in only one of the five 
NCI-recommended panels of microsatellite markers in tumors.
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in tumors with high levels of mucin, false negatives can oc-
cur.16 False negatives also can occur with MSH6 germline mu-
tations, as they may have MSI-L results.37 And unlike with IHC 
testing, an abnormal MSI test results does not suggest which 
gene to test. 
Absence of MLH1 on IHC was also noted to have a low gene 
mutation detection rate. In time it became possible to distin-
guish sporadic from a hereditary etiology in individuals with 
absent expression of MLH1 on IHC testing. This abnormal IHC 
result is frequently due to two somatic events: BRAF muta-
tion Val600Glu (V600E) or MLH1 promoter hypermethylation. 
They both are common explanations of absent MLH1 expres-
sion in patients without a germline MLH1 mutation, partic-
ularly among those diagnosed with CRC after age 50. BRAF 
mutations and MLH1 promoter hypermethylation are thought 
to be rare in Lynch syndrome-related cancers, though each 
has been seen in individuals with Lynch syndrome. In spite 
of these reported cases, the presence of a BRAF mutation or 
MLH1 promoter hypermethylation essentially rules out the di-
agnosis of Lynch syndrome.38-43
Remember, as abnormalities in IHC are suggestive, con-
firmatory diagnosis of Lynch is only by positive mutation 
on gene sequencing. The first patents for gene sequencing 
of MLHH-1 and MSH2 were filed in 1997 and 1999. Commer-
cial launching then ensued in 2000.44 Commercial testing for 
MSH6 soon followed. Due to technical complexity of PMS2 
testing, commercial testing of the PMS2 gene did not become 
available until 2009.
An estimated 50% of Lynch syndrome mutations are 
found in MLH1,45 40% in the MSH2 gene45 7%-10% in the MSH6 
gene,30,33,46 5% in the PMS2 gene47 and 1-3% EPCAM.36,48,49 
Screening for Lynch syndrome
From 2000-2005 many centers were using family histories and 
pathological criteria by the Revised Bethesda Criteria to guide 
testing on tumors for MSI and or IHC. If these were abnormal, 
genetic counseling and then gene testing were performed. 
There was much controversy during this time whether MSI 
and IHC could be performed without patients’ consent. There 
was concern that these studies themselves could lead to a di-
agnosis of a hereditary disorder, which could have insurance 
implications. With Heather Hampel’s study on all colorectal 
cancers,17 the new definition of Lynch syndrome (confirmed 
by a proven MMR gene mutation),9 EGAPP18 and GINA19 led 
the movement towards universal screening. The finding that 
a family history (a standard on initial history and physicals) 
that met Amsterdam criteria led to a diagnosis of Lynch syn-
drome with the same frequency as documenting abnormal 
MSI/IHC testing (about 60% of the time) also added to the 
defense to perform MSI and IHC without formal consent.17,50 
Therefore, patients were only defined to have the Lynch mu-
tation once mutation was noted by gene sequencing. There 
is consensus that once germline testing is to be considered, 
genetic counseling is a standard.51   
The United States Law began to recognize the importance 
and consequences of gene testing. GINA, passed in 2008 and 
enacted in 2009, prohibits health insurers from using genetic 
information (e.g., genetic test results, family history) to de-
termine insurability. It does have shortcomings that genetic 
counselors explain as part of their normal consenting pro-
cess. If patients have a lapse of coverage, genetic diseases can 
be considered a pre-existing condition. It does not prevent 
companies from using the diagnosis of Lynch syndrome to 
help underwrite their disability, life insurance, and long-term 
policies. Since its inception, The Affordability Care Act of 2010 
also allowed new coverage options to individuals who have 
been uninsured for at least six months because of a pre-ex-
isting condition. This program will serve as a bridge to 2014, 
when rejecting insurance coverage due to pre-existing condi-
tions will be prohibited.52
Hampel’s and De la Chappelle’s 2005 study16 on all colorec-
tal cancers resected amongst the major hospitals in Ohio 
led to some very important discoveries and the feasibility 
of screening for Lynch syndrome on all CRC patients. It was 
then updated in 2008.17 In 2005, initially all colorectal can-
cers underwent MSI testing. If they were MSI-H or MSI-L they 
underwent IHC for MLH1, MSH2, MSH6 and PMS2-, sequenc-
ing of MLH1, MSH2, and MSH6, and methylation analysis of 
MLH1 promoter region if IHC for MLH1 was abnormal. If IHC 
revealed a lack of PMS2 and a presence of MLH1, PMS2 gene 
mutation was analyzed. In addition, those that were MSS but 
met Bethesda or Amsterdam criteria underwent IHC testing.  
In 2008 an additional 500 CRC patients were screened, this 
time with MSI and IHC. Another 372 patients who were MSS 
and had normal IHC (or IHC not completed secondary to lack 
of tissue) underwent gene testing for two of the most com-
mon MMR gene mutations in their series. One is American 
Founder Mutations (MSH2) and the other was another com-
mon mutation in MSH2.
Combining the findings of the 2005 with the 2008 study 
patients, it was noted that the MSI-H prevalence was 12.7% in 
all colorectal cancers, and the prevalence of Lynch syndrome 
was at a minimum of 2.8%. In 2005, 10 out of the 23 identified 
Lynch syndrome patients were over 50 years of age and 5 out 
of 23 did not meet Bethesda or Amsterdam criteria. Testing 
only by MSI or IHC would each have missed two probands. 
MSI lacked sensitivity if there was significant mucin in the 
specimen and therefore careful dissection by pathology was 
recommended. For each proband, 5.79 at-risk family mem-
bers were contacted; over 3 members per proband were diag-
nosed with Lynch. 
Not only was prevalence now established, it also illustrat-
ed the feasibility of testing all colon cancers for Lynch syn-
drome.  1566 patients out 1700 patients agreed to participate. 
Only 2 out of 23 probands from 2005 study refused contact 
to be made with at-risk family members. Of the 199 mem-
bers who were contacted and received counseling, only two 
of these refused to undergo gene testing. These findings led 
to discussion about health care policy and Lynch syndrome. 
The Evaluation of Genomic Applications in Practice and Pre-
vention Group (EGAPP) published its position statement in 
2009, concluding with moderate certainty that testing newly 
diagnosed CRC patients could provide moderate population 
benefit. It did not address the cost-effectiveness of a universal 
screening program.18
In 2009, Myundura et al.53 reported that universal testing 
would detect nearly twice as many Lynch patients as target-
ing only those with younger age of onset of CRC. Also, the 
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incremental cost effectiveness ratio was comparable to other 
preventive services. Their decision model looked at 4 main 
strategies:1. IHC testing for all MMR genes and utilizing BRAF 
if MLH1 was abnormal 2. IHC testing for all 4 MMR genes and 
proceeding to gene sequencing if abnormal, or 3. MSI-H test-
ing and proceeding to gene sequencing if abnormal or strat-
egy 4, testing all CRC with gene sequencing.  
For each of the four strategies the models calculated costs 
and outcomes using many of the data from Hampel’s papers, 
i.e. average relatives contacted, tested, calculating costs of 
testing, surveillance and treatment for CRC. For each strat-
egy the cost-effectiveness ratios (in US dollars) were $23,206, 
$23,221, $28,291 and $ 79,651, respectively. See Table 6 below. 
Cost-effectiveness ratios associated with Lynch syndrome 
testing strategies among new diagnosed colorectal cancer pa-
tients and testing and surveillance for CRC among their first-
degree relatives.  See Table 7.
Analyzing the incremental cost-effectiveness ratio (ICER) 
using strategy 1. the incremental cost-effectiveness compar-
ing to the next best strategy varies from about $18,000 to 
$50,000. Comparing this to colonoscopy screening (individu-
als older than 50 and at every 10-year intervals) is $25,000 
per LY saved. They note in these same articles that many 
analysts use a critical value of $50,000 or $100,000 per LY 
or QALY as a criterion of cost-effectiveness. They concluded 
that universal testing for Lynch syndrome is well within the 
range of acceptable ICERs for preventive services in the Unit-
ed States. As with many studies looking at cost effectiveness 
of genetic testing, the true saving come to those which oper-
ate in a hereditary center module, as there is active attempts 
to reach out to at-risk family members. The cost savings is 
truly made with the site specific testing of the at-risk rela-
tives once a mutation is known. Site specific testing is much 
cheaper, frequently one tenth of the cost for diagnosing the 
proband’s mutation. 
Current diagnostic strategies 
As the preceding text shows, there are many ways to arrive 
at a diagnosis of Lynch syndrome, from going straight to 
germline genetic testing of all Lynch genes to targeting the 
germline testing based on results from IHC, BRAF and MLH1 
hypermethylation testing. According to their availability and 
policies, individual institutions follow a host of algorithms. 
Some hospitals only perform MSI or IHC on specimens as re-
quested by clinicians on a case-by-case basis. Some institu-
tions follow Bethesda Criteria and may perform MSI, IHC, or 
both. There is a trend after the EGAPP working group papers 
that more institutions are performing universal screening on 
ALL colorectal cancers (and some performing IHC on endo-
metrial), with MSI or IHC or both. Some sites have expanded 
to IHC on all or a subset of endometrial cancers.
Imperative in these strategies is that the abnormal values 
are reported to a clinician or counselor who can appropriately 
interpret these results. At Duke University we currently per-
form MSI and IHC on all colorectal cancers, by endoscopic 
biopsy or surgical resection specimen, with all results being 
sent to our genetic counselors. Clinicians in gastroenterology, 
surgery and medical oncology all agreed to allow the counsel-
ors to contact their patients as an extension of their practice. 
This allows the treating clinician to maintain “ownership” 
over the follow-up of abnormal results, removes pathologists 
from a position of directly influencing patient care, and main-
tains HIPAA compliance. 
Many institutions begin Lynch syndrome evaluation by 
performing IHC testing based on the rationale that an ab-
normal IHC test will lead to cheaper germline genetic test-
ing.  Cost of gene sequencing and deletion/duplication test-
ing for all 4 genes varies by laboratory, but is at least $4500. 
Testing a single gene, as directed by an abnormal IHC result, 
can decrease this cost by at least $2000. Cost of site-specific 
genetic testing for a known familial mutation ranges from 
about $150-$500.  This illustrates the cost saving as hereditary 
centers reach out to at-risk family members.
For those found to lack MLH1 staining on IHC, centers 
vary whether reflexively BRAF/MLH1 hypermethylation is 
performed or whether genetic counseling ensues prior to 
performing BRAF. The presence of BRAF mutation/MLH1 hy-
permethylation virtually excludes Lynch syndrome. But if the 
individual has a strong family history or early onset cancer, 
heightened surveillance may still prevail. This is because 
Table 6 – Incremental cost-effectiveness ratios of the 4 testing strategies of universal to no testing, of age-targeted 
testing to no testing, age-targeted testing to previous strategy in dollars per life-year saved.
Strategies Description of 
testing strategy a
Incremental cost-effectiveness 
ratio of universal testing relative 
to no testing and relative to 
previous strategy, dollars per 
life-year saved  
Incremental cost-effectiveness 
ratio of age-targeted testing 
relative to no testing and 
relative to previous strategy, 
dollars per life-year saved
Incremental cost-effectiveness 
ratio of universal testing 
relative to age-targeted testing 
and relative to previous 
strategy, dollars per life-year 
saved
1 IHC, BRAF testing 
and sequencing
$22,552 and $22,552 $7,832 and $7,832 $37,010 and $37,010
2 IHC testing and 
sequencing
$23,321 and $273,915 $7,944 and $60,569 $38,411 and $429,973
3 MS1 testing and 
sequencing
$41,511 and $764,917 $11,680 and $168,905 $70,792 and $1,192,575
4 Genetic sequencing 
for 4 genes
$142,289 and $737,025 $44,902 and $252,643 $237,278 and $1,192,575
a Sequencing includes detection of large deletions and rearrangements.
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while it is rare, MLH1 hypermethylation can be present in a 
Lynch syndrome patient as the second hit.36,39 On the con-
trary, MSH2 methylation has been found to be the second hit 
in approximately 24% of MSH2 related cancers. It has not been 
found in sporadic cancers.54
Because of the proteins of the MMR are frequently pres-
ent as complexes/dimers, loss of one is often associated 
with a loss of the partner MMR protein. Loss of expression of 
MLH1 is almost always associated with loss of PMS2 expres-
sion. Loss of MSH2 expression is almost always accompanied 
by loss of MSH6 expression. On the other hand, loss of PMS2 
expression or MSH6 expression is frequently seen without 
the accompanying loss of MLH1 or MSH2, respectively. Loss 
of MSH2 and MSH6 usually indicates a germline MSH2 mu-
tation. Loss of MSH6, only, usually indicates a mutation in 
MSH6. Non-sporadic loss of MLH1 and PMS2 (i.e., normal 
BRAF and MLH1 hypermethylation testing) is typically due to 
an MLH1 or PMS2 mutation. Loss of PMS2, only, usually rep-
resents a PMS2 mutation. Because of this relationship with 
paired complexes, some centers strategize by performing 
IHC first for PMS2 and MSH6. If both are present, no further 
testing is done. If one is absent, the other partner of the di-
mer is tested. For example, absent expression of MSH6 would 
lead to IHC testing of MSH2. 
Although there are clearly benefits to beginning the Lynch 
syndrome evaluation with MSI and IHC screening on an af-
fected individual’s colon or endometrial tumor, or even an 
adenoma with high-grade dysplasia,55,56 this is not always 
possible. When another tumor within the Lynch syndrome 
spectrum is available, MSI and IHC testing can still guide fur-
ther testing when abnormal. The same logic applies to per-
forming MSI and IHC on metastases from a colorectal prima-
ry. When no Lynch spectrum tumor, adenoma or metastasis is 
available for MSI and IHC testing, direct germline genetic test-
ing of the Lynch-associated genes is the next step. However, 
interpretation of germline results is not always straightfor-
ward. Variants of uncertain clinical significance can confound 
interpretation. And normal germline results in an individual 
with high prior probability of detecting a mutation (e.g., be-
cause of meeting Amsterdam II criteria or having colon can-
cer with histologic features noted in the revised Bethesda cri-
teria) still leave the possibility of an undetectable germline 
mutation. This complicates risk management for the patient 
and their first-degree relatives, as it is unclear whether they 
should be managed as if they have Lynch syndrome. 
There are various mathematical models that have been 
devised using patient’s personal cancer history and family 
members to predict risks of gene mutations in Lynch syn-
drome. Some have found these helpful to determine if gene 
sequencing (with its inherent short-coming without tissue 
availability) is worthwhile. When IHC MSI cannot be per-
formed on tissue due to inavailability, these are PREMM1,2,6, 
MMRpredict, and MMRpro.
PREMM1,2,6
 The model is based on data from 4539 individuals undergoing 
genetic testing of MSH2, MLH1, and MSH6 through a commer-
cial laboratory. This model uses the proband’s and second-
degrees relatives history of Lynch syndrome-related cancers 
(colon, endometrial, stomach, ovarian, small intestine, uri-
nary tract/kidney, bile ducts, glioblastoma, sebaceous gland 
tumors, and pancreas) and age of onset of colon and endo-
metrial cancers. MSI and IHC testing is not included. Based on 
genotype/phenotype data, this model provides specific likeli-
hood estimates for detecting a mutation in each of the MMR 
genes (MLH1, MSH2, MSH6). Using a 5% mutation probability 
as a standard for MMR testing, the model has an estimated 
sensitivity of 90% and a specificity of 54%.57 Using family his-
tory it can also estimate risk of MMR gene mutation in an 
unaffected individual.
MMRpredict 
Uses a population-based cohort diagnosed with CRC before 
age 55 years who were tested for MLH1, MSH2, and MSH6 mu-
tations. Data from MSI and IHC testing and the presence of 
CRC and/or endometrial cancer in first-degree relatives can 
be incorporated. This model can only be used in affected in-
dividuals. Because the model is based on those diagnosed be-
fore 55 years of age, it is unclear how accurate the model is for 
tumors diagnosed in older individuals.58
Table 7 – Interval cost-effectiveness ratios relative to next most effective strategy and relative to no Lynch syndrome 
testing for detecting Lynch syndrome in newly diagnosed patients with colorectal cancer.
Change made to baseline model 
assumptions
Incremental cost-effectiveness ratios relative to next most effective strategy and relative 
to no Lynch syndrome testing (in parentheses) strategy for detecting Lynch syndrome in 
newly diagnosed patients with colorectal cancer a
IHC, BRAF testing 
and then sequencing 
(strategy 1)
IHC testing and then 
sequencing  
(strategy 2) 
MSI testing and then 
sequencing  
(strategy 3)
Genetic sequencing 
for four genes 
(strategy 4)
Median laboratory list price – 
universal vs. no testing
$30,331 ($30,331) $170,300 ($30,740) $786,030 ($49,272) $1,082,378 ($200,037)
Median laboratory list price – 
universal vs. age-targeted testing
$50,563 ($50,563) $280,003 ($51,359) $1,435,324 ($85,391) $1,803,950 ($341,837)
Cascade testing (12 relatives) – 
universal vs. no testing
$12,332 ($12,332) $129,346 ($12,663) $340,298 ($20,470) $329,869 ($63,773)
Cascade testing (12 relatives) – 
universal vs. age-targeted testing
$18,778 (18,778) $181,543 ($19,379) $579,096 ($33,291) $508,402 ($104,909)
a Sequencing includes detection of large deletions and rearrangements.
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MMRpro 
Uses the data obtained from clinic and population avail-
able in the literature with cancer risk estimates based on pen-
etrance from a meta-analysis of five large Lynch syndrome 
studies. It uses the presence of CRC and other cancers in the 
proband, first- and second-degree relatives, age of onset, and 
IHC and MSI testing to estimate the likelihood of identifying a 
germline mutation in MLH1, MSH2, or MSH6. It allows calcula-
tion of a family member’s risk to inherit the germline muta-
tion and the risk to develop colon or endometrial cancer.59   
Risks of CRC
In the early 20th century, at the time Warthin’ first described 
Family G, gastric cancer was a common cancer in Lynch syn-
drome families. Just as sporadic cancer has seen a decline, 
so has gastric cancer in Lynch syndrome. The more common 
secondary cancers are colorectal, ovarian, gastric, and renal 
system (transitional cell of renal pelvis and ureter) and se-
baceous cysts adenoma and adenocarcinomas. A mnemonic 
quite useful to remember these is COUGaRS: Colorectal, Ovar-
ian, Uterine, Gastric and Renal(Urinary-transitional cell), Se-
baceous tumors. Other cancers include medulloblastoma 
brain cancers, biliary cancers, and small bowel. More recent 
small increases in prostate and breast has been reported. Cur-
rently, colorectal cancer is overall the most common cancer in 
Lynch syndrome. 
Earlier in the history of Lynch syndrome, the mean age for 
CRC was thought to be 43 years old. Lynch describes average 
age of 44.6 years in his Family R.5 We now know this is a false 
low average due to selection bias. As we all had a higher de-
gree of concern for the younger patients with CRC it falsely 
lowered the mean age of occurrence. When Hampel excluded 
the probands in her study, and with aggressive discovery of 
relatives with Lynch who already had CRC, the average age of 
cancer in the nonprobands was 61 years.60
Previously patients with Lynch syndrome were thought to 
have a ~80% risk of cancer by the age of 80. As our knowl-
edge and diagnostic capabilities have been augmented, our 
numbers are tempered. Also, looking at risks based on spe-
cific mutations, more individualized risks can be predicted. 
These risks also vary by sex. For example, MLH1 and MSH2 
mutations have CRC risks of 66-69% in men, 43-53% in women 
with average age of 61 years.60,61 Overall, MSH6 and PMS2 have 
an attenuated risk. CRC cancer risks for patients with MSH6 
mutations are 44% for males and 20% for females.62 Patients 
with MSH6 mutations also present with later ages of onset 
and a more distal distribution. They are also associated with 
MSI-L tumors.46,63 The risk in a patient with a PMS2 mutation 
was 15%-20% by 70 years of age.47 The newly noted mutation 
in EPCAM has higher penetrance for CRC. Kempers estimated 
from a cohort of 194 individuals with EPCAM mutations that 
the cumulative risk of CRC by 70 is 75%.64
Risks of non-colonic cancers
See Table 8.65
Endometrial cancer
Endometrial cancer (EC) is the second most common cancer 
in Lynch syndrome. Women have a 25-60% lifetime risk (Table 
8).60,61,66,67 Just as studies on high-risk families found a younger 
age of onset for colon cancer that was reputed in population 
studies, the same occurred with EC. Early studies reported av-
erage age of 48 years old; the population-based studies now 
show average age is 62.60,67
Also similar to colon cancer, endometrial cancer has vari-
ous risks based on mutation site.  MLH1, MSH2, MSH632 have 
approximately a 44% risk for endometrial CA. Others have 
noted a slight increase risk of endometrial for MSH6 vs. MLH1, 
and MSH2.46 Kemper64 found a 12% risk for EPCAM mutations. 
Women who in their lifetime have both colon and endo-
metrial cancer have an equal chance of having either can-
cer first.69,62 For those women who are diagnosed with their 
colorectal cancer first, their subsequent risk of later EC is 26% 
within 10 years of their CRC diagnosis.70 The lifetime risk (70 
years) for a woman to have colon or endometrial cancer was 
noted to be 73% in Stoffel’s study.61
Gastric cancer
Gastric cancer in Lynch patients is usually intestinal type adeno-
carcinoma, though Capelle has reported that in the Netherlands, 
up to 20% can present with a diffuse gastric carcinoma histol-
ogy.71,72,73 Microsatellite instability is noted in these tumors.74
Overall, estimates for gastric cancer risk in heterozygotes for 
an MLH1 or an MSH2 mutation range from 6% to 13%. Men with 
MSH2 mutation have the highest risks.72,73 A high incidence of H 
pylori infection, or Asian populations also have increased inci-
dence.75 The mean age of diagnosis is 56 years old.71 
Ovarian cancer
The risk for ovarian cancer is roughly twice in MSH2 (8%-11%) 
versus MLH1 mutation (4-6%). The mean age is 42.5 years with 
Table 8 – Comparative risks of cancer types of general 
population and  patients with MLH1 and MSH2 
mutation, and mean age of onset  of each cancer with 
patients with MLH12 and MSH2 mutations. 
Cancer Type General 
population  
risk
Lynch syndrome (MLH1 and 
MSH2 heterozygotes)
Risk Mean age of 
onset
Colon 5.5% 52-82% 44-61 years
Endometrium 2.7% 25-60% 48-62 years
Stomach < 1% 6-13% 56 years
Ovary 1.6% 4-12% 42.5 years
Hepatobiliary 
tract
< 1% 1.4-4%% Not reported
Urinary tract < 1% 1-4% ~55 years
Small bowel < 1% 3-6% 49 years
Brain/central 
nervous 
system
< 1% 1-3% ~50 years
Sebaceous 
neoplasms
< 1% 1-9% Not reported
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30% diagnosed before the age of 35.72 The histology distribu-
tion is similar to those with sporadic ovarian cancer, though 
borderline does not seem to be associated with Lynch syn-
drome.76 One metanalysis paper noted ovarian cancers with 
mismatch repair deficiency presented in earlier stages.77 The 
only study that compared survival did not reveal a survival 
advantage for Lynch patients with ovarian cancer versus the 
sporadic ovarian cancer.78 
Renal-urinary tract cancers
The urinary tract cancers most associated with Lynch syn-
drome are transitional carcinomas of the ureter and renal pel-
vis. One Dutch study suggested an increased risk with bladder 
cancer. Their Lynch patient with bladder cancer did show MSI 
and/or loss of stain on IHC that corresponded to the germline 
mutation. Bladder cancer, however, is not listed as one of the 
Amsterdam or Bethesda criteria.76,79 Watson notes a smallest 
risk estimate of 1% in women with MLH1 mutation and then 
up to 27% in men with MSH2 mutation.72
Small bowel cancer
Lifetime risk of small bowel cancer is 3-6%, though >100 times 
the risk of the general population.72 50% of the small bowel 
cancers are within the duodenum and jejunum, within the 
reach of an upper endoscopy.80 The majority in adenocarcino-
ma80 incidence is similar between MLH1 and MSH2 mutations 
and rare in MSH6 and PMS2.81
Pancreatic and biliary cancer
A few studies have revealed an increased risk of pancreatic 
cancer, and family clustering is noted. Geary noted a seven-
fold increase risk in their Lynch syndrome patients over the 
general population.82,83 However, other studies have not dem-
onstrated an increased risk.84
Brain tumors
The risk for brain tumors is estimated at approximately 2%.16 
Risks may be underestimated as 26% of the time when the 
age of onset is before 25 years of age.72 The most common 
histology is glioblastoma, and is rarely associated with micro-
satellite instability.85 It is the third cause of cancer death for 
Lynch patients in a large Dutch cohort.86
Sebaceous skin neoplasias
This includes sebaceous adenomas, sebaceous epitheliums, 
sebaceous carcinomas, and keratoacanthomas.87,88 Seba-
ceous neoplasms associated with Lynch syndrome exhibit 
MSI and IHC.89,90 The data on the frequency of sebaceous 
neoplasms in individuals with Lynch syndrome are limited. 
Studies have found that between 1% and 9% of individu-
als with a germline mutation in an MMR gene have a seba-
ceous neoplasm.91,92 Individuals with Lynch syndrome and 
a sebaceous neoplasm have Muir-Torre syndrome, which 
was initially thought to be a separate entity. IHC testing of 
sebaceous adenomas has shown that a significant propor-
tion is sporadic. Among those with abnormal IHC testing in a 
sebaceous neoplasm, Lynch syndrome mutation carriers are 
more likely than those with sporadic presentation to have 
multiple sebaceous neoplasms and a personal or family his-
tory of a Lynch spectrum cancer.93
Additional cancer risks  
Hematologic cancers, laryngeal cancer and sarcomas have 
been suggested. Due to rarity of presentations, it is difficult 
to determine the magnitude of risks.94,95 Nilbert96 did note de-
fective MMR in the histopathology of six of eight sarcomas in 
individuals with Lynch syndrome.
Breast cancer
The relationship between breast cancer and Lynch syndrome 
is unresolved.97,98,99 Studies have not consistently demon-
strated a higher than expected incidence. Walsh, however, did 
demonstrate that in breast cancer of patients with a mutation 
in a MMR gene, 51% did demonstrate a loss of immunohisto-
chemical staining for the protein corresponding to the gene in 
which a germline mutation occurs.100
Variants of Lynch 
Muir-Torre syndrome is the terminology used to describe a 
Lynch syndrome patient who also has sebaceous neoplasms 
of the skin. The types of sebaceous skin neoplasias described 
include: sebaceous adenomas, sebaceous epitheliomas, seba-
ceous carcinomas, and keratoacanthomas.87,88 MSH2 mutation 
is the most common mutation noted.92
Turcot syndrome is defined as CRC or colorectal adenomas 
in addition to tumors of the central nervous system. This can 
be due to APC gene mutation as seen in FAP, or due to MMR 
gene mutation associated as a Lynch syndrome.101 Therefore, 
the clinical colonic presentation varies from numerous colon-
ic polyps to a single polyp or CRC. The brain cancer associated 
with APC mutation tends to be medulloblastomas; mutations 
of the MMR gene tend to present with glioblastomas. The 
brain tumors associated with mutations in a mismatch repair 
gene exhibit MSI.101,102 
Homozygous mismatch repair mutations: rare individuals 
who are homozygous for mutations in MLH1, MSH2, MSH6, 
and PMS2 have been reported. Affected individuals often 
have onset of colon or small bowel cancer prior to the second 
decade of life. One third of children with biallelic mutations 
have been reported to have more than ten polyps. Also as-
sociated is Hematologic cancer, brain tumors, and café-au-lait 
macules.103,104
Survival
When matched stage for stage, colon cancers in individu-
als with Lynch syndrome are associated with a better prog-
nosis than sporadic colon cancer.105 This is an unexpected 
finding because the poorly differentiated histology of Lynch 
syndrome-related colon cancers is typically associated with a 
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poor prognosis.  Due to the mutation in the MMR genes, Lynch 
syndrome cancers do not respond to typical chemotherapeu-
tic agents like 5-fluorouracil, in fact, they may do worse.106
Surveillance
Surveillance is an important part of the management of a 
patient with Lynch syndrome. Optimal surveillance requires 
a multidisciplinary approach involving primary care physi-
cians, gastroenterologists, gynecologists and colorectal sur-
geons. An excellent resource for surveillance is available on 
the National Comprehensive Cancer Network website (www.
nccn.org). There are no strong data for surveillance for many 
of the Lynch syndrome associated cancers and recommenda-
tions outside of colon and endometrium are based on expert 
opinion.
CRC Surveillance 
Since 1977 Dr. Lynch proposed starting colonic surveillance as 
early as 20 years of age.5 Current surveillance recommenda-
tions also start in Lynch patients as early as age 20-25 (or 10 
years prior to family member’s cancer diagnosis, whichever is 
earlier) with colonoscopy. Intervals are every two years, until 
40, then yearly afterwards. The short interval is due to the ac-
celerated progression of polyp to cancer as noted by Jass in 
1992.107 Some recommend starting surveillance at the age of 
30 in patients with MSH6 or PMS2 mutations since the average 
age of onset of colon cancer is somewhat later. Colonoscopy 
is repeated every 1-2 years. After diagnosis of CRC and subse-
quent resection, surveillance should occur on a yearly basis. 
Regular surveillance is proven to reduce both incidence (11% 
vs 27%) and death (2% vs 12%) from  CRC.108 
Gynecological Surveillance  
There is no clear evidence to support routine screening or 
surveillance for endometrial or ovarian cancer. Some rec-
ommend annual transvaginal US and endometrial sam-
pling at 30-35 years of age.46,47 Studies on the effectiveness 
of transvaginal ultrasound examination and endometrial 
biopsy have had conflicting results. In most screening stud-
ies, patients presented with symptoms before or during 
their surveillance with transvaginal ultrasound or endome-
trial sampling.109,110 
Ovarian cancer
No specific ovarian cancer screening trials have been con-
ducted in women with Lynch syndrome. Of note, screening 
for ovarian cancer using CA-125 blood tests and transvaginal 
ultrasound examination has not been effective in other high-
risk populations such as women with a BRCA1 or BRCA2 mu-
tation.111
Gastric cancer 
There are no strong data for gastric cancer surveillance. 
Schulmann has noted that 50% of his patients with small 
bowel cancer were noted proximally within the reach of an 
upper endoscope.80 While there are no studies on the efficacy 
of surveillance, enteroscopy is a consideration noted by the 
NNCN starting at age 30-35 and performing every 2-3 years. 
More frequent intervals can be considered if chronic inflam-
mation, atrophic gastropathy and/or intestinal metaplasia 
is noted. Many insurance companies are now covering this 
procedure. Also capsule endoscopy every 2-3 years starting at 
30-35 years of age can be considered for surveillance of the 
distal small bowel. 
Urinary collecting system 
A urinalysis can be performed on an annual basis starting at 
30-35 years of age (NCCN 2011). There are no studies to prove 
efficacy and survival. As it is a noninvasive test, recommenda-
tions remain. 
Other cancers 
Lindor et al.46 recommend beginning annual examination at 
age 21 for features of sebaceous. The National Comprehen-
sive Cancer Network recommends beginning annual physical 
exam for such features at 25-30.112 There is no current data to 
make a standard recommendation in the case of pancreati-
cobiliary cancers. There are programs that are embarking as 
a research study to perform surveillance for Lynch and other 
high-risk patients for pancreatic cancer.113,114
Surgery for prophylaxis and for treatment
Gynecological cancer
Women with Lynch syndrome who are undergoing colon 
cancer are usually offered the choice of prophylactic hys-
terectomy and bilateral salpingo-oophorectomy.  Also, once 
the patient is past childbearing age or post-menopausal, 
prophylactic hysterectomy and bilateral salpingo-oopher-
ectomy can be considered as a risk-reducing measure. 
Schmeler115 noted in their case-control study of 315 women 
with Lynch syndrome, 1/3 had prophylactic hysterectomy 
with bilateral salpingo-oophorectomy. After 10 years of fol-
low-up, there were no gynecological cancers in the women 
with prophylactic surgery, though there was 33% incidence 
of endometrial cancer and 5% ovarian cancer in the con-
trol group. Chen and colleagues116 also noted the efficacy 
of prophylactic surgery. They concluded that one diagnosis 
of endometrial cancer was prevented for every 6 surgeries, 
and one ovarian cancer for every 28 surgeries.  Most would 
recommend for the pre-menopausal women who choose 
prophylactic surgery to be placed on hormonal replace-
ment until the age of 50.30,46,47,117
CRC
Dr. Lynch first described that, with good family history, rec-
ommendations of colon removal may decrease the incidence 
of cancer.5 This was prior to significant use of colonoscopy in 
the prevention of colon cancer as the snare was just invented 
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in 1969.118 Currently prophylactic colon resection is not rec-
ommended. The extent of surgery to be performed once a CRC 
is diagnosed is still under investigation (NCCN 2011). There 
are pros and cons to consider in regards to segmental vs. total 
or subtotal colectomy. There is a balance of quality of life, and 
the risks of metachronous disease.
The initial risks of CRC as stated earlier are substantially 
decreased with frequent surveillance by colonoscopy. There 
is no reason not to believe that metachronous cancers are 
not also reduced with frequent surveillance. Engel noted in 
their Lynch patients that if a metachronous cancer was found 
during yearly surveillance colonoscopy it was earlier in stage, 
with 95% discovered in Stage I and Stage II.119 
Parry120 notes in their comparison of segment versus ex-
tensive resection that the metachronous risk was reduced by 
31% for each 10cm of bowel removed. While they state there 
was no difference in the frequency of endoscopy in the two 
groups, the interval was truly only estimated and not record-
ed. The weakness in this study is the frequency of scoped was 
assumed to be distributed uniformly in the period between 
the first and last age of endoscopy. Those metachronous can-
cers that were discovered, as in Engel’ study, were predomi-
nantly in early stages: 27 (47%) at stage I, 20 (35%) at stage II 
and 10 (18%) at stage III. Of the 10 patients who developed 
AJCC stage III metachronous CRC (mean follow-up 12 [SD 10] 
years), six reported 1-2 yearly lower endoscopy, one reported 
no endoscopy and for three it was unknown. At 5 years after 
surgical resection, 49 (98%) who had extensive colectomy and 
327 (98%) who had segmental colectomy were alive (p1⁄40.8). 
At 10 years, 49 (98%) who had extensive colectomy and 322 
(97%) who had segmental colectomy were alive (p1⁄40.7). 
Therefore one can conclude a more substantial resection may 
limit second surgery but no proof in increased survival can be 
gathered by this study. 
Maeda121 constructed a state-transition (Markov) model 
based on assumptions obtained from available data sources 
and published literature. They compared segmental colec-
tomy (SEG) to a total abdominal colectomy (TAC) for quality 
adjusted life years (QALYs). They concluded that, for young 
(30-year-old) patients with Lynch syndrome, mean survival 
was slightly better with TAC than with SEG (34.8 v 35.5 years). 
Their QALYs were approximately equivalent, with QALYs per 
patient of 21.5 for SEG and 21.2 for TAC. With advancing age, 
SEG becomes a more favorable strategy. 
There have been no studies to date that prove that a more 
extensive resection will translate to greater colon cancer sur-
vival. Therefore, case  by case management based on patients’ 
age of presentation, stage of initial cancer presentation, cur-
rent bowel habits and continence, willingness to undergo 
close surveillance and patient desires need to be considered 
and discussed with the patient. 
Risk adjustments
We are all aware that there is always an interplay between 
environment and genetics. We at this time cannot change our 
genes, but can we decrease the risks that our genes have in 
store for us through our environment? There are many rea-
sons to stop smoking. We encourage our Lynch syndrome pa-
tients to stop smoking as it was one of the three risks factors 
CRC noted by Watson et al.122 The other two factors were male 
sex and MLH1 mutation. The hazard ratio of being a male was 
1.58, MLH1 vs. MSH2 was 2.07 and tobacco use, 1.43.
Chemoprevention
Women who take a combined oral contraceptive pill can 
lower their risk of endometrial and ovarian cancer. This risk 
seems to decrease with longer duration. While the ovaries 
enjoy a permanent protective effect, this affect persists 
for about 5 years after stopping oral contraceptives. While 
there is no evidence to suggest oral contraceptives in Lynch 
syndrome patients, its use is not contraindicated in Lynch 
syndrome patients. Other risks factors such as smoking and 
history of thromboembolism need to be considered prior to 
prescribing.117,122
Professor Burn and team have been looking over the years 
at the use of aspirin and starch to prevent CRC in patients 
with known mutations. His study was a two by two double 
blinded randomized study of starch/ASA, Starch/placebo, pla-
cebo/ASA, placebo/placebo.  Patients received 30 g of starch 
(novelose) and 600 mg of aspirin. The study was designed to 
note if this decreased the incidence of advanced adenomas 
or carcinomas. Initial results of 746 Lynch patients after 4 
years did not reveal a decreased risk with the use of aspirin. 
In 2011, after a few patients had reached 10 years of follow-up, 
the results were reviewed once more in regards to their risks 
of CRC and other Lynch related cancers. Post-intervention 
review revealed 13 of 342 allocated aspirin and 27 of 329 al-
located had CRC. 38 participants developed cancer at a site 
other than the colorectal (additionally, two participants had 
CRC and another Lynch syndrome cancer) of which 16 were 
randomly assigned to aspirin and 22 to aspirin-placebo. The 
study does not comment on the compliance of colonoscopy 
but interestingly even for non-CRC the risks decreased. From 
this they recommend 600 mg of ASSA per day for patients 
who can tolerate the regimen. CAPP3 is underway to evaluate 
different dosages as doses <600 have been implied in their 
study to be also effective. The optimum dose and duration is 
to be studied in CAPP3.123,124
Family X 
At the beginning of the paper we discussed the importance 
of Lynch to be diagnosed with confirmation of MMR gene 
mutation. It is now known that not all patients who meet 
the Amsterdam Criteria are Lynch syndrome patients. This 
is best illustrated with Family X. Family X was first described 
by Lindor.125 In her large database of patients that met Am-
sterdam criteria, there were two groups. One group was 
MSI, the other was MSS. Comparing these patients and their 
at-risk relatives (3422 first- and second-degree relatives) in 
these two groups, a few striking differences were noted. A 
standardized incidence ratio was calculated and compared 
to the general population. The families that were MSI-H had 
a greatly increased risk of CRC with a SIR 6.1. Also increased 
were cancers of the uterus, stomach, urinary tract, ovary, 
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and small bowel, pancreas and liver.  The MSS family had a 
CRC risk with a SIR of 2.3. There were no other cancers noted 
with increased risk in this group. The onset of cancer in the 
MSI0H group was also earlier (48.7) vs. 60.7 in the second 
group. The lower risk ratio for CRC and the absent risk of the 
secondary cancers. In retrospect this is the Lynch syndrome 
I patients that were discussed many years ago. 
Lindor dispelled the notion that all families meeting 
Amsterdam I criteria are a distinct homogenous group and 
could now be further subdivided by their MSI status. The 
families that do not have an MMR defect (MSI-L/MSS in this 
study) have a lower risk of CRC, and a later onset. Therefore 
colonoscopy recommendations are to start colonoscopies 
for the at-risk family members at 5-10 years earlier than 
the earliest diagnosis of CRC in the family and occur every 
5 years, if normal. 
During the same year Llor et al.126 studied 1309 newly di-
agnosed CRC in Spain in which 25 probands fit Amsterdam I 
or II criteria. Fifteen (60%) of the tumors were MSS with the 
remaining MSI-H. All MSS tumors expressed MLH1, MSH2 or 
MSH6. MSS probands were older at diagnosis (67.8 vs. 64.8), 
had more left sided colon cancers (86.7 v evenly spread), 
were well differentiated (33% vs. 0%), and lacked lymphocyt-
ic infiltrate (0% vs. 50%). There was no difference in synchro-
nous or metachronous cancers. When looking at relatives, 
more families in the MSS group had less affected members 
than in the MSI-H group (18% vs. 31.5%) and were diagnosed 
at a later age (60.2vs 53.8). All extracolonic tumors found 
in both groups were endometrial and this occurred more 
frequently in the MSI group than in the MSS group (5.1% 
v3.3%). These findings echoed Lindor’s study that MSS fami-
lies fulfilling Amsterdam criteria appear to be representing 
a syndrome separate from Lynch syndrome. Later studies, 
including a 2007 study by Valle et al.,127 continue to bolster 
this important distinction.
Summary
Much has been learned since the Human Genome Proj-
ect, and much more is to be discovered. As more variants of 
unknown significance are categorized as deleterious muta-
tions, more patients will be properly diagnosed as Lynch 
syndrome. As we have better definitions of the mutations, 
and long-term follow-up on the affected patients, we will 
become better in tailoring patients’ risks and therefore tai-
loring their management. With a better understanding of 
their pathophysiology we may then be able to intervene 
with better prevention strategies. To meet the goals of in-
creasing the diagnosis of Lynch syndrome to then in turn 
decrease incidence of cancer in these families, a group 
of institutions formed the Lynch Syndrome Surveillance 
Network in the United States in 2011. Through universal 
screening and a common shared database these goals can 
be met.  
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